First In Class Integrase Inhibitor, ‘Isentress’(R) (Raltegravir), Recommended For European Licence For The Treatment Of HIV
‘Isentress’(R) (raltegravir), Merck Sharp & Dohme Limited’s (MSD) treatment for HIV infection, has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Evaluation Agency (EMEA) in Europe. [click link for full article]
More: continued here
Filed under: HIV / AIDS on November 20th, 2007